StockNews.com Begins Coverage on Chimerix (NASDAQ:CMRX)

Analysts at StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX - Get Free Report) in a research note issued to investors on Thursday. The brokerage set a "sell" rating on the biopharmaceutical company's stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a "neutral" rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Price Performance

CMRX stock remained flat at $8.54 during trading on Thursday. The business's 50 day simple moving average is $7.93 and its 200 day simple moving average is $4.37. The stock has a market capitalization of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. Chimerix has a 12 month low of $0.75 and a 12 month high of $8.55.

Chimerix (NASDAQ:CMRX - Get Free Report) last announced its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. Sell-side analysts forecast that Chimerix will post -0.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 20,760 shares of company stock valued at $91,175 in the last ninety days. 13.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Chimerix

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bender Robert & Associates acquired a new stake in shares of Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Chimerix in the 4th quarter valued at approximately $59,000. Jane Street Group LLC acquired a new stake in Chimerix in the 4th quarter valued at approximately $62,000. Diadema Partners LP acquired a new stake in Chimerix in the 4th quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC acquired a new stake in Chimerix in the 4th quarter valued at approximately $130,000. Institutional investors and hedge funds own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.